-
Unified Dyskinesia Rating Scale: Application for FDA Designation as a Preferred Scale for Assessing Dyskinesia in Parkinson’s Disease
… Rationale: Several scales are available for the rating of dyskinesia in Parkinson’s disease, and the designation of a … that best fits the needed criteria to asses all aspects of dyskinesia. Hypothesis: Given the strong clinimetric profile …
-
Pre-clinical Validation of a Novel Target for Dyskinesia Induced by Levodopa
… of abnormal involuntary movements known as levodopa-induced dyskinesia (LID), which can be as debilitating as the disease itself. Dyskinesias arise when activity in a brain region called the …
-
Dyskinesia
… Dyskinesia is uncontrolled, involuntary movement that may … will develop this complication, and the experience of dyskinesia varies. New and emerging treatments aim to help …
-
Bitopertin to Alleviate Dyskinesia in Parkinson's Disease
… Study Rationale: Levodopa-induced dyskinesia is abnormal involuntary movements that can affect … disease after years of treatment. Available therapies for dyskinesia are only partly effective to alleviate the …
-
Potential of Novel Insulin Sensitizers to Treat Dyskinesia
… same time) or reverse (when given later) the L-DOPA-induced dyskinesia in a pre-clinical model. This is a novel insulin … is over-activated in the striatum during L-DOPA-generated dyskinesia, and that this over-activation plays a causative …
-
Validation of a Novel Pre-Clinical Model of Dyskinesia in PD
… beta-arrestin2 expression would alter both levodopa-induced dyskinesia and locomotion. Our hypotheses were proven … over-expression of beta-arrestin2 reduced the occurrence of dyskinesias but at the same time enhanced locomotion. These …